LabCorp announced it will purchase contract research company Covance Inc. for approximately $6.1 billion in cash and stock.
Diagnostics company LabCorp announced on Nov. 3, 2014 that it will purchase contract research organization Covance to create “the world’s leading healthcare diagnostics company,” according to a Covance press release. Together, the combined company will provide medical testing services and offer drug development commercialization services.
The focus of the combined company is enhanced data delivery, both to physicians and drug sponsors. These data for clinical trials will be collected more efficiently through the partnership and will help facilitate personalized medicine, drug development, and drug commercialization. According to Covance, this will improve R&D productivity, as both ends of the drug development process will be addressed.
“This transaction provides LabCorp with immediate scale and a comprehensive market-leading platform in the $141 billion biopharmaceutical R&D market, while at the same time achieving the new sources of revenue, broader payer mix, and greater international presence we have long pursued," said LabCorp Chairman and CEO David P. King in the press release. "As a combined company, we will be well positioned to respond to and benefit from the fundamental forces of change in our business, including payment for outcomes, pharmaceutical outsourcing, global trial support, trends in pharmaceutical R&D spending, personalized medicine, and big data and informatics."
Indeed, the partnership will create more genomic drug evidence in a market that increasingly demands more evidence-based medicine. The partnership may also help further LabCorp’s goal to optimize patient drug regimens, especially for expensive personalized medicines. Covance has spent much of 2014 expanding on its biologics capabilities and adding to its “molecule management teams,” which are made up of scientific experts in the field of drug development.
The acquisition, which is subject to Covance shareholder approval, is expected to close in the first quarter of 2015.
Source: Covance
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.